PRIMORDIUM Trial Evaluates Apalutamide Plus ADT for High Risk Biochemical Recurrence of Prostate Cancer After Prostatectomy – Boris Hadaschik
Boris Hadaschik discusses the ongoing PRIMORDIUM phase three trial. The study explores the efficacy of adding six months of apalutamide to ADT in men with high-risk biochemical recurrence post-prostatectomy, evidenced by PSMA-PET imaging. This innovative trial integrates PET imaging not just at baseline but as a primary endpoint, marking a significant leap in utilizing advanced diagnostics to…